Intellia Therapeutics (NASDAQ:NTLA) Hits New 52-Week Low at $19.31

Intellia Therapeutics, Inc. (NASDAQ:NTLA) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $19.31 and last traded at $19.65, with a volume of 181329 shares. The stock had previously closed at $19.83.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group restated a “buy” rating and set a $73.00 target price on shares of Intellia Therapeutics in a research note on Thursday, June 27th. Evercore ISI raised shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th. Royal Bank of Canada lowered their price target on shares of Intellia Therapeutics from $60.00 to $54.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. Finally, Stifel Nicolaus reduced their target price on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.77.

Intellia Therapeutics Price Performance

The stock has a fifty day simple moving average of $23.47 and a two-hundred day simple moving average of $24.57. The firm has a market capitalization of $2.02 billion, a P/E ratio of -3.78 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The firm had revenue of $7.00 million for the quarter, compared to the consensus estimate of $19.68 million. The firm’s quarterly revenue was down 48.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.40) EPS. As a group, sell-side analysts expect that Intellia Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Blue Trust Inc. increased its holdings in shares of Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after acquiring an additional 1,398 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Intellia Therapeutics by 763.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after acquiring an additional 1,550 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in shares of Intellia Therapeutics by 22.1% during the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after acquiring an additional 472 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Intellia Therapeutics by 1,322.0% during the second quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock valued at $59,000 after acquiring an additional 2,459 shares in the last quarter. Finally, EntryPoint Capital LLC increased its holdings in shares of Intellia Therapeutics by 61.1% during the first quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock valued at $113,000 after acquiring an additional 1,563 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.